



Supplementary Figure 1: Actual Antibiotic Use versus Adjusted Antibiotic Use of Anti-MRSA Agents in 2016 Ranked by Actual Antibiotic Use



a-AU, adjusted antibiotic use; AU, antibiotic use; DOT, days of therapy; MRSA, methicillin resistant *Staphylococcus aureus*; PD, patient-days


Supplementary Figure 2: Actual Antibiotic Use versus Adjusted Antibiotic Use of Anti-VRE Agents in 2016 Ranked by Actual Antibiotic Use



Hospital 9 was removed from figure as an outlier: AU 10, a-AU 165


a-AU, adjusted antibiotic use; AU, antibiotic use; DOT, days of therapy; PD, patient-days; VRE, vancomycin resistant enterococci

Supplementary Figure 3: Actual Antibiotic Use versus Adjusted Antibiotic Use of Antipseudomonal Beta-Lactams in 2015 Ranked by Actual Antibiotic Use




a-AU, adjusted antibiotic use; APBL, antipseudomonal beta-lactams; AU, antibiotic use; DOT, days of therapy; PD, patient-days

Supplementary Figure 4: Actual Antibiotic Use versus Adjusted Antibiotic Use of Carbapenems in 2015 Ranked by Actual Antibiotic Use




a-AU, adjusted antibiotic use; AU, antibiotic use; DOT, days of therapy; PD, patient-days

Supplementary Figure 5: Actual Antibiotic Use versus Adjusted Antibiotic Use of Anti-MRSA Agents in 2015 Ranked by Actual Antibiotic Use



a-AU, adjusted antibiotic use; AU, antibiotic use; DOT, days of therapy; MRSA, methicillin resistant *Staphylococcus aureus*; PD, patient-days

Supplementary Figure 6: Actual Antibiotic Use versus Adjusted Antibiotic Use of Anti-VRE Agents in 2015 Ranked by Actual Antibiotic Use



a-AU, adjusted antibiotic use; AU, antibiotic use; DOT, days of therapy; PD, patient-days; VRE, vancomycin resistant enterococci